MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. More Details
Flawless balance sheet and slightly overvalued.
Share Price & News
How has MEI Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MEIP's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: MEIP exceeded the US Biotechs industry which returned 39.7% over the past year.
Return vs Market: MEIP exceeded the US Market which returned 17.2% over the past year.
Price Volatility Vs. Market
How volatile is MEI Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StEarnings Update: MEI Pharma, Inc. (NASDAQ:MEIP) Just Reported And Analysts Are Trimming Their Forecasts
2 weeks ago | Simply Wall StMEI Pharma, Inc. (NASDAQ:MEIP) Analysts Just Trimmed Their Revenue Forecasts By 0.9%
3 weeks ago | Simply Wall StThe MEI Pharma (NASDAQ:MEIP) Share Price Has Gained 41% And Shareholders Are Hoping For More
Is MEI Pharma undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MEIP ($3.12) is trading below our estimate of fair value ($28.52)
Significantly Below Fair Value: MEIP is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MEIP is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: MEIP is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MEIP's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MEIP is overvalued based on its PB Ratio (4.4x) compared to the US Biotechs industry average (3.4x).
How is MEI Pharma forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MEIP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MEIP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MEIP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MEIP's revenue (46.8% per year) is forecast to grow faster than the US market (9.9% per year).
High Growth Revenue: MEIP's revenue (46.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MEIP's Return on Equity is forecast to be high in 3 years time
How has MEI Pharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MEIP is currently unprofitable.
Growing Profit Margin: MEIP is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MEIP is unprofitable, and losses have increased over the past 5 years at a rate of 11.5% per year.
Accelerating Growth: Unable to compare MEIP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MEIP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-3.2%).
Return on Equity
High ROE: MEIP has a negative Return on Equity (-58.83%), as it is currently unprofitable.
How is MEI Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: MEIP's short term assets ($208.6M) exceed its short term liabilities ($23.3M).
Long Term Liabilities: MEIP's short term assets ($208.6M) exceed its long term liabilities ($108.2M).
Debt to Equity History and Analysis
Debt Level: MEIP is debt free.
Reducing Debt: MEIP has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable MEIP has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: MEIP is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 0.9% per year.
What is MEI Pharma current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MEIP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate MEIP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MEIP's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MEIP's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MEIP's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dan Gold (66 yo)
Dr. Daniel P. Gold, also known as Dan, Ph.D. has been the Chief Executive Officer and President of MEI Pharma, Inc. (Alternate Name: Marshall Edwards Inc.), a subsidiary of Novogen Limited since April 26, ...
CEO Compensation Analysis
Compensation vs Market: Dan's total compensation ($USD1.85M) is about average for companies of similar size in the US market ($USD1.96M).
Compensation vs Earnings: Dan's compensation has been consistent with company performance over the past year.
|CFO & Secretary||3.42yrs||US$842.61k||0.033% |
|COO & General Counsel||2.17yrs||US$1.31m||0.021% |
|Chief Medical Officer||9.25yrs||US$674.28k||0.030% |
|Vice President of IR & Corporate Communications||no data||no data||no data|
|Senior VP of Marketing||no data||no data||no data|
|Senior Vice President of Regulatory Affairs||5.92yrs||no data||no data|
|Senior Vice President of Clinical Development||4.5yrs||no data||no data|
Experienced Management: MEIP's management team is seasoned and experienced (5.2 years average tenure).
|Independent Non-Executive Director||1.17yrs||no data||0% |
|Independent Non-Executive Director||2.58yrs||US$158.94k||0.056% |
|Independent Non-Executive Director||7.25yrs||US$166.44k||0% |
|Independent Non Executive Director||5.75yrs||US$161.44k||0% |
|Independent Non-Executive Chairman||4.75yrs||US$183.94k||0.013% |
|Independent Non-Executive Director||7.58yrs||US$161.44k||0.0089% |
|Independent Non-Executive Director||8.92yrs||US$168.94k||0.026% |
|Non-Executive Director||0.42yr||no data||no data|
Experienced Board: MEIP's board of directors are considered experienced (5.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 52.8%.
MEI Pharma, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: MEI Pharma, Inc.
- Ticker: MEIP
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$351.069m
- Shares outstanding: 112.52m
- Website: https://www.meipharma.com
Number of Employees
- MEI Pharma, Inc.
- 11455 El Camino Real
- San Diego
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MEIP||NasdaqCM (Nasdaq Capital Market)||Yes||Common Stock||US||USD||Dec 2003|
|MMIA||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Dec 2003|
|0JW9||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Dec 2003|
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase de ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/01 00:08|
|End of Day Share Price||2020/09/30 00:00|